Eisenmenger syndrome is a long-term complication of an unrepaired heart defect for the person born with congenital. The congenital heart defects associated with Eisenmenger syndrome cause blood to circulate abnormally in your heart and lungs.
According to the American Heart Association, about 9 of every 1,000 babies born in the U.S. have a congenital heart defect. Congenital heart problem is found among new born babies who are affected during the pregnancy. Congenital problems are most common birth defect. The rise in the number of patients suffering from mild CHD’s and increasing focus on R&D activities related to the development of advanced drugs are factors expected to drive the growth of the global eisenmenger syndrome treatment market. About 1 in 4 babies with CHD have a critical CHD. Infants with critical CHDs generally need surgery or other procedures in their first year of life. Several factors are responsible for the patients suffering from Eisenmenger syndrome the complexity of cardiac defects appears to be central. The deficiency related to Iron is often associated with blood hyper-viscosity in these patients and represents a risk factor for adverse outcomes. Major players are investing high for development products such as blood thinning agents and endothelin receptor antagonist in order to treat the problems. Increasing in clinical trials related to development of new products is expected to augment the growth of target market. In 2021, The U.S. Food and Drug Administration approved “Pradaxa” a blood thinning agent. The approval of Pradaxa is expected to help pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots.
Government of developed and developing countries is spending high on development of healthcare sector. Their approach towards providing advanced care to patients along with better diagnostic facilities is gaining traction. Diagnosis tests such as blood tests, electrocardiogram (ECG), and chest x-ray are gaining attraction among consumers. Awareness related to these testing is increasing and is widely adopted by consumers. Factors such as lack of developed infrastructure and complex regulations by the government for product approval are expected to hamper the growth of global eisenmenger syndrome treatment market. In addition, high cost associated to development of equipments is expected to challenge the growth of target market. However, increasing investment by major players for development of innovative solutions and high spending on healthcare infrastructure development are factors expected to create new opportunities for players operating in the eisenmenger syndrome treatment market over the forecast period. In addition, increasing partnership and agreements between players in order to enhance the business presence is expected to support the revenue growth of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global eisenmenger syndrome treatment market due to high patient pool suffering from chronic diseases. Presence of many players operating in the country and introducing new solutions are factors expected to augment the regional market growth. In addition, increasing acquisition activities by major players in order to enhance the business and enhance the customer base is expected to support the growth of eisenmenger syndrome treatment market.
The market in Asia Pacific is expected to witness faster growth in the target market due to increasing government spending on healthcare sector. In addition, favorable business policies by the government and emergence of small and mid size players with enhanced solution is expected to support the growth of eisenmenger syndrome treatment market.
The global eisenmenger syndrome treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Eisenmenger Syndrome Treatment Market Segment Analysis, 2019
The global eisenmenger syndrome treatment market is segmented into drug type, diagnosis, and distribution channel. The drug type segment is divided into antiarrhythmic agents, blood thinning agents, endothelin receptor antagonist, and others. Among product type the blood thinning agents segment is expected to account for significant revenue share in the global eisenmenger syndrome treatment market. The diagnosis segment is bifurcated into blood tests, electrocardiogram (ECG), chest x-ray, echocardiogram, computerized tomography (CT) scan, magnetic resonance imaging (MRI), cardiac catheterization, and walking test. The players profiled in the report are Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc., Mylan N.V., and Bayer AG.
Market By Drug Type
Blood Thinning Agents
Endothelin Receptor Antagonist
Market By Distribution Channel
Market By Diagnosis
Computerized tomography (CT) scan
Magnetic resonance imaging (MRI)
Rise in number of patient suffering from mild CHD’s and increasing focus on R&D activities related to development of advanced drugs are factors expected to drive the growth of global eisenmenger syndrome treatment market.
In drug type the blood thinning agents segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Actelion Pharmaceuticals Ltd., Gilead Sciences, Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
The North America is expected to account for major revenue share in the global market.
Factors such as lack of developed infrastructure and complex regulations by the government for product approval are expected to hamper the growth of global eisenmenger syndrome treatment market.